Value of Transvaginal Two-Dimensional Contrast-Enhanced Ultrasonography in Diagnosing Atypical Ovarian Corpus Luteum Hematoma

Liu, Hui; Xiang, Hong; Mu, Ruixue; Tuoerhan, Palida; Zeng, Qianqian; Zhou, Haisheng; Hu, Rong; Shahai, Gulinaer

doi:10.1155/2018/3120579

Cited by 3 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transvaginal two-dimensional ultrasound is currently a common screening method for malignant tumors. The distribution and nature of tumors can be observed by two-dimensional ultrasound, and the nature of a mass can be comprehensively judged by the characteristics of whether the mass has an envelope or not ( 14 ).…”

Section: Discussionmentioning

confidence: 99%

Diagnostic Value of Two-Dimensional Transvaginal Ultrasound Combined with Contrast-Enhanced Ultrasound in Ovarian Cancer

Shahai

Liu

et al. 2022

Front. Surg.

Self Cite

View full text Add to dashboard Cite

ObjectiveExplore the value of two-dimensional transvaginal ultrasound combined with contrast-enhanced ultrasound in the differential diagnosis of ovarian cancer, so as to provide the basis for clinical diagnosis and treatment of ovarian cancer.MethodsA total of 100 suspected ovarian cancer patients who were admitted to our hospital from January 2019 to December 2021 were selected as the research subjects, including 62 ovarian cancer patients (ovarian cancer group) and 38 ovarian benign tumor patients (benign group). Two-dimensional vaginal ultrasound and contrast-enhanced ultrasound were performed in both groups. The differences in PI, RI, EDV, PSV, and VM parameters of the two groups as well as those of patients with ovarian cancer of different grades were compared. Record the contrast-enhanced ultrasound parameters such as AT, TTP and IMAX, and determine the diagnostic value.ResultsThe PI and RI of the ovarian cancer group were lower than those of the benign ovarian tumor group, and the EDV, PSV and VM of the ovarian cancer group were higher than those of the benign ovarian tumor group (p < 0.05). The PI and RI of the patients in stage I–II of the ovarian cancer group were higher than those in stage III–IV, and the EDV, PSV and VM were lower than those in the patients in stage III–IV, with statistical significance (p < 0.05). The results of contrast-enhanced ultrasound showed that the AT and TTP values in the ovarian cancer group were significantly shorter than those in the benign group, and the peak intensity was significantly higher than that in the benign group, and the differences were statistically significant (p < 0.05). The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of two-dimensional ultrasound combined with contrast-enhanced ultrasound in the diagnosis of ovarian cancer were high, 95.16%(59/62), 86.84%(33/38), 92.19%(59/64), 91.67%(33/36) and 92.00%(92/100), respectively.ConclusionContrast-enhanced ultrasound to some extent makes up for the deficiencies of conventional ultrasound, is helpful to detect early ovarian cancer, and can be used for the differential diagnosis of small ovarian tumors with difficult two-dimensional ultrasound diagnosis. Two-dimensional ultrasound combined with contrast-enhanced ultrasound can effectively improve the detection rate and differential diagnosis value of ovarian cancer, which is of great significance in the early diagnosis and differentiation of ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic Value of Two-Dimensional Transvaginal Ultrasound Combined with Contrast-Enhanced Ultrasound in Ovarian Cancer

Shahai

Liu

et al. 2022

Front. Surg.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Rupture and hemorrhage of corpus luteum cyst is one of the common acute abdominal diseases in gynecology [1,2], which occurs in the middle and late menstrual cycle, and is often seen in women of childbearing age, often under the inducement of exercise and sexual life. Clinically, the diagnosis of the disease mainly depends on laboratory and ultrasound examination [3].…”

Section: Research Backgroundmentioning

confidence: 99%

Analysis of the Diagnosis and Treatment of Recurrent Rupture and Hemorrhage of Ovarian Corpus Luteum Cyst Induced by Imatinib

Xia¹,

Huang²,

Song³

et al. 2021

JGO

View full text Add to dashboard Cite

Objective: Rupture and hemorrhage of corpus luteum cyst is one of the common acute abdominal diseases in gynecology, which occurs in the middle and late menstrual cycle, and is often seen in women of childbearing age, often under the inducement of exercise and sexual life. There are few reports about drug-induced rupture and hemorrhage of corpus luteum cyst. Chronic myeloid leukemia (CML) is a common hematological disease and a chronic clonal myeloproliferative disease. Imatinib is a first-line drug for the treatment of chronic myeloid leukemia, and its efficacy and safety have been widely recognized, but there are still some adverse reactions. Among them, it is rare that the drug causes ovarian corpus luteum rupture and bleeding. In our clinical work, we just treated a patient with recurrent ovarian luteal cyst rupture and bleeding from imatinib, and followed up the whole course of the patient's pathogenesis, diagnosis and treatment effect. Therefore, this paper analyzes the clinical data and treatment of the case, in order to improve the clinical understanding and treatment of recurrent ovarian luteal cyst rupture and hemorrhage induced by imatinib. Methods: The clinical data and treatment of 1 case of recurrent ovarian corpus luteum cyst rupture bleeding from imatinib were analyzed, and the therapeutic effect was followed up. Results: Imatinib led to 6 times of corpus luteum rupture bleeding, which were successfully treated with conservative treatment. After taking Diane-35, the patient did not have corpus luteum rupture bleeding once again. And no adverse drug reactions. Conclusion: Imatinib can cause recurrent ovarian luteal cyst rupture and bleeding, conservative treatment is often effective. Diane-35 can effectively prevent and treat recurrent ovarian luteal cyst rupture and bleeding induced by imatinib. And the incidence of adverse drug reactions was low. But the specific mechanism that imatinib causes rupture of recurrent ovarian luteal cyst is unclear.

show abstract

Ultrasound screening of ovarian cancer

Bäumler

Gallant

Druckmann³

et al. 2019

Hormone Molecular Biology and Clinical Investigation

View full text Add to dashboard Cite

Ovarian cancer has a high mortality rate. The most common serous type spreads rapidly throughout the peritoneal cavity when 5-year survival is 10%. If diagnosed in earlier stages where the cancer is still confined to the ovary, this survival rate is about 90%. This is the reason to be interested in screening at earlier stages in the average-risk general population. Thus, annual transvaginal ultrasound (TVS) alone or as a multimodal screening test following serum carbohydrate antigen 125 (CA125) has been investigated. Ultrasound lacks sensitivity and specificity; new contrast-enhanced approaches might improve these. When the serum marker is combined with ultrasound and interpreted by a rise in the level rather than by a fixed cut-off, improved sensitivity and specificity and a late but not significant reduction in mortality are observed. Further investigations could highlight the interest of a shorter than annual screening, of a long-term follow-up and new contrast-enhanced ultrasound techniques.

show abstract

Value of Transvaginal Two-Dimensional Contrast-Enhanced Ultrasonography in Diagnosing Atypical Ovarian Corpus Luteum Hematoma

Cited by 3 publications

References 20 publications

Diagnostic Value of Two-Dimensional Transvaginal Ultrasound Combined with Contrast-Enhanced Ultrasound in Ovarian Cancer

Diagnostic Value of Two-Dimensional Transvaginal Ultrasound Combined with Contrast-Enhanced Ultrasound in Ovarian Cancer

Analysis of the Diagnosis and Treatment of Recurrent Rupture and Hemorrhage of Ovarian Corpus Luteum Cyst Induced by Imatinib

Ultrasound screening of ovarian cancer

Contact Info

Product

Resources

About